Nothing Special   »   [go: up one dir, main page]

EP0744942A1 - Controlled release hydrogel formulation - Google Patents

Controlled release hydrogel formulation

Info

Publication number
EP0744942A1
EP0744942A1 EP95908570A EP95908570A EP0744942A1 EP 0744942 A1 EP0744942 A1 EP 0744942A1 EP 95908570 A EP95908570 A EP 95908570A EP 95908570 A EP95908570 A EP 95908570A EP 0744942 A1 EP0744942 A1 EP 0744942A1
Authority
EP
European Patent Office
Prior art keywords
drug
hydrogel
pharmaceutical composition
ionizable compound
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP95908570A
Other languages
German (de)
French (fr)
Other versions
EP0744942A4 (en
EP0744942B1 (en
Inventor
Chih-Ming Chen
Charles S.L. Chiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22721188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0744942(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of EP0744942A1 publication Critical patent/EP0744942A1/en
Publication of EP0744942A4 publication Critical patent/EP0744942A4/en
Application granted granted Critical
Publication of EP0744942B1 publication Critical patent/EP0744942B1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Definitions

  • the present invention is concerned with a hydrogel based pharmaceutical dosage system that provides sustained release of pharmaceuticals without the need to use special coatings or structures that add to the cost of making a sustained release formulation.
  • the in vitro release rates are not zero-order release rates because the initial rate of release of the drug tends to be much higher than the subsequent rate of release of the drug.
  • hydrogels have been used to prepare sustained release formulations. These formulations have commonly exhibited an "initial burst effect" which causes a non-linear release rate of a drug. In order to avoid the initial burst effect, hydrogels have been used in combination with mechanical devices and polymeric coatings to control the rate of drug release in order to modify the release rate characteristics and provide a substantially zero-order controlled release formulation.
  • the present invention provides a method for modifying the release characteristics of a hydrogel by adding an effective amount of an ionizable compound to the hydrogel and drug formulation.
  • the invention comprises a method for the modification of the rate of release of a drug from a hydrogel which is based on the use of an effective amount of a pharmaceutically acceptable ionizable compound that is capable of providing a substantially zero-order release rate of drug from the hydrogel.
  • Figure 1 is a graphical representation of the release rates of tablets of diltiazem hydrochloride which are based on unmodified hydrogel, i.e., hydroxypropylmethyl cellulose and modified hydrogel which that has been modified by the addition of certain ionizable compounds that are capable of modifying the rate of release of a drug from a hydrogel.
  • Figure 2 is a graphical representation of the release rate of a tablet prepared as described in Example 2.
  • the hydrogel that is the basis of the formulation of the present invention is any hydrogel which causes a drug to exhibit a substantially zero-order release rate when the hydrogel is modified by the addition of an effective amount of a non-toxic, pharmaceutically acceptable ionizable compound which is capable of modifying the release rate of the drug from the hydrogel.
  • Suitable hydrogels include hydroxypropylmethyl cellulose, sodium alginate, xanthan gum and the like.
  • the ionizable compound may be any non-toxic inorganic or organic compound that is compatible with the hydrogel and affects the dissolution rate of a tabletted drug that includes a drug, a hydrogel and said ionizable compound.
  • the ionizable compound should have a pH in water of from about 2 to not greater than about 11 and preferably a pH of from 4-8 when one molar equivalent is dissolved in 1 liter of water.
  • the ionizable compounds include alkali metal chlorides, magnesium chloride, calcium chloride, organic acids such as citric, succinic, fumaric, malic, maleic, glutaric, lactic and the like, alkali metal sulfates such as sodium sulfate, alkali metal alkyl sulfates wherein the alkyl group is from 1 to 14 carbon atoms, such as sodium methyl sulfate, sodium lauryl sulfate and the like as well as dioctyl sodium sulfosuccinate, dihydrogen sodium phosphate and monohydrogen sodium phosphate. It is to be understood that the ionizable compound may be a single compound or a mixture of two or more materials that provide the desired release characteristics.
  • any drug may be used in the practice of the invention which is compatible with the hydrogel and exhibits a substantially zero-order controlled release when tabletted with the hydrogel and an effective amount of the non-toxic, pharmaceutically acceptable ionizable compound.
  • drugs that may be utilized are the calcium channel blocking drugs such as diltiazem hydrochloride and verapamil hydrochloride.
  • the dosages to be employed are sufficient to maintain a therapeutic level of the drug in a patient.
  • the amount of the ionizable compound that is employed will be between 1 and 50% and preferably 5 to 15% by total weight of the hydrogel forming material, the drug and the ionizable compound.
  • the drug will generally be from 10 to 90% by total weight of the hydrogel forming material, the drugand the ionizable compound.
  • the hydrogel will be the difference of the total weight of the formulation less the combined weight of the drug and the ionizable compound.
  • hydroxypropylmethyl cellulose and sodium chloride are employed to prepare a tablet formulation of diltiazem, it has been found that a blend of 26.09g of diltiazem hydrochloride; 6.5g of sodium chloride; 3g of sodium lauryl sulfate and 30g of hydroxypropylmethyl cellulose may be employed to provide a substantially zero-order release tablet.
  • the amount of the hydrogel and the ionizable compound that are used may be determined by preparing a series of tablets using varying amounts of hydrogel and ionizable compound in combination with the selected drug.
  • the release characteristics may be determined separately using simulated gastric fluid (pH 1.2- without enzymes) ;simulated intestinal fluid (pH 7.5-without enzymes) and a pH 6.2 buffer solution.
  • the "paddle method" from USP XXII which is incorporated by reference, may be used to determine the release characteristics of a given formulation and by the addition of or subtraction of increasing amounts of the ionizable compound to a particular tablet formulation, the release curve for a particular drug may be shifted to a zero-order release product.
  • compositions of the invention will contain an effective amount of the drug and an amount of the hydrogel and ionizable compound that may be made into tablets which will have a substantially zero-order release of the selected drug.
  • the tabletted product may contain an inert solid diluent such as lactose, dextrose, maltose, fructose, corn starch, rice starch and the like.
  • Other conventional additives such as binding agents such as polyvinylpyrrolidoine, starch, gelatin, microcrystalline cellulose and the like may be added to the tablet formulation.
  • coloring agents such as stearic acid, palmitic acid, magnesium stearate, and the like may be added to the tabletting composition in amounts which are determined to produce the desired effect. Tablets may be made using conventional tabletting machines and appropriately sized dies.
  • Blend A A blend of diltiazem hydrochloride dispersed in hydroxypropylmethyl cellulose (HPMC) (100,000cps as measured in a 2wt% solution in water) was prepared by first separately passing the ingredients through a #40 US Standard mesh sieve and thereafter blending the mixture in a V-blender for 5 minutes.
  • HPMC hydroxypropylmethyl cellulose
  • HPMC Metal stearate 27.0wt% Lactose,Anhydrous 35.1wt% Magnesium stearate 1.0wt%
  • the powder was blended and compressed into capsule shaped tablets (0.70" x 0.29") with the compression set at twotons.
  • An in vitro dissolution test was carried out separately using 900ml of an enzyme free simulated gastricfluid (pH 1.2); 900ml of an enzyme free simulatedintestinal fluid (pH 7.5) and a buffer solution (pH 6.2) substantially as described in USP XXII.
  • the USPXXII method that was used was apparatus No. 2.
  • the dissolution curve was prepared by determining at preset intervals the amount of dissolved diltiazem.
  • Fig. 1 The results are shown on Fig. 1 as curve A.
  • tablets were prepared which contained 10% by weight of sodium chloride (B); 10% by weight of Na HPO (C) : 10% by weight of sodium lauryl sulfate (D) in place of 10% by weight of the anhydrous lactose that was employed in Blend A.
  • the dissolution characteristics were determined according to the procedure set forth above and the characteristics are curves B, C and D of Fig. 1, respectively.
  • the presence of the ionizable compound has the effect of flattening the release curve by preventing the initial burst of the active drug which results when a tablet, made from unmodified HPMC, is employed with diltiazem hydrochloride.
  • Example 2 The ingredients were blended and compressed into 0.28" round tablets using the procedure described in Example 1. The tablets were tested according to the procedure of Example 1 and the dissolution curve is set forth in Fig. 2. The results show that the tablets produced according to Example 2 have a substantially zero-order release rate.
  • Verapamil HC1 40.00wt.% HPMC 22.22wt.%

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention is directed to a method for the modification of the rate of release of a drug from a hydrogel which is based on the use of an effective amount of a pharmaceutically acceptable ionizable compound that is capable of providing a substantially zero-order release rate of drug from the hydrogel.

Description

CONTROLLED RELEASE HYDROGEL FORMULATION
BACKGROUND OF THE INVENTION
The present invention is concerned with a hydrogel based pharmaceutical dosage system that provides sustained release of pharmaceuticals without the need to use special coatings or structures that add to the cost of making a sustained release formulation.
When an unmodified hydrogel is used as a pharmaceutical carrier for many diverse types of pharmaceuticals, the in vitro release rates are not zero-order release rates because the initial rate of release of the drug tends to be much higher than the subsequent rate of release of the drug.
In the prior art, hydrogels have been used to prepare sustained release formulations. These formulations have commonly exhibited an "initial burst effect" which causes a non-linear release rate of a drug. In order to avoid the initial burst effect, hydrogels have been used in combination with mechanical devices and polymeric coatings to control the rate of drug release in order to modify the release rate characteristics and provide a substantially zero-order controlled release formulation.
The present invention provides a method for modifying the release characteristics of a hydrogel by adding an effective amount of an ionizable compound to the hydrogel and drug formulation.
SUMMARY OF THE INVENTION
The invention comprises a method for the modification of the rate of release of a drug from a hydrogel which is based on the use of an effective amount of a pharmaceutically acceptable ionizable compound that is capable of providing a substantially zero-order release rate of drug from the hydrogel.
Accordingly it is a primary object of this invention to provide a method for the modification of the rate of release of a drug from a hydrogel.
It is also an object of this invention to provide a modifier for the rate of release of a drug from a hydrogel which will modify the rate of release of a drug from the hydrogel.
It is also an object of this invention to provide a novel controlled release pharmaceutical dosage unit which does not require the use of a wax or a water insoluble resin coating.
These and other objects of the invention will become apparent from a review of the appended specification.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graphical representation of the release rates of tablets of diltiazem hydrochloride which are based on unmodified hydrogel, i.e., hydroxypropylmethyl cellulose and modified hydrogel which that has been modified by the addition of certain ionizable compounds that are capable of modifying the rate of release of a drug from a hydrogel.
Figure 2 is a graphical representation of the release rate of a tablet prepared as described in Example 2.
DETAILED DESCRIPTION OF THE INVENTION
The hydrogel that is the basis of the formulation of the present invention is any hydrogel which causes a drug to exhibit a substantially zero-order release rate when the hydrogel is modified by the addition of an effective amount of a non-toxic, pharmaceutically acceptable ionizable compound which is capable of modifying the release rate of the drug from the hydrogel.
Suitable hydrogels include hydroxypropylmethyl cellulose, sodium alginate, xanthan gum and the like.
The ionizable compound may be any non-toxic inorganic or organic compound that is compatible with the hydrogel and affects the dissolution rate of a tabletted drug that includes a drug, a hydrogel and said ionizable compound. The ionizable compound should have a pH in water of from about 2 to not greater than about 11 and preferably a pH of from 4-8 when one molar equivalent is dissolved in 1 liter of water. The ionizable compounds include alkali metal chlorides, magnesium chloride, calcium chloride, organic acids such as citric, succinic, fumaric, malic, maleic, glutaric, lactic and the like, alkali metal sulfates such as sodium sulfate, alkali metal alkyl sulfates wherein the alkyl group is from 1 to 14 carbon atoms, such as sodium methyl sulfate, sodium lauryl sulfate and the like as well as dioctyl sodium sulfosuccinate, dihydrogen sodium phosphate and monohydrogen sodium phosphate. It is to be understood that the ionizable compound may be a single compound or a mixture of two or more materials that provide the desired release characteristics.
Any drug may be used in the practice of the invention which is compatible with the hydrogel and exhibits a substantially zero-order controlled release when tabletted with the hydrogel and an effective amount of the non-toxic, pharmaceutically acceptable ionizable compound. Examples of drugs that may be utilized are the calcium channel blocking drugs such as diltiazem hydrochloride and verapamil hydrochloride. The dosages to be employed are sufficient to maintain a therapeutic level of the drug in a patient. Generally the amount of the ionizable compound that is employed will be between 1 and 50% and preferably 5 to 15% by total weight of the hydrogel forming material, the drug and the ionizable compound. The drug will generally be from 10 to 90% by total weight of the hydrogel forming material, the drugand the ionizable compound. The hydrogel will be the difference of the total weight of the formulation less the combined weight of the drug and the ionizable compound. When hydroxypropylmethyl cellulose and sodium chloride are employed to prepare a tablet formulation of diltiazem, it has been found that a blend of 26.09g of diltiazem hydrochloride; 6.5g of sodium chloride; 3g of sodium lauryl sulfate and 30g of hydroxypropylmethyl cellulose may be employed to provide a substantially zero-order release tablet.
The amount of the hydrogel and the ionizable compound that are used may be determined by preparing a series of tablets using varying amounts of hydrogel and ionizable compound in combination with the selected drug. The release characteristics may be determined separately using simulated gastric fluid (pH 1.2- without enzymes) ;simulated intestinal fluid (pH 7.5-without enzymes) and a pH 6.2 buffer solution. The "paddle method" from USP XXII which is incorporated by reference, may be used to determine the release characteristics of a given formulation and by the addition of or subtraction of increasing amounts of the ionizable compound to a particular tablet formulation, the release curve for a particular drug may be shifted to a zero-order release product. The pharmaceutical compositions of the invention will contain an effective amount of the drug and an amount of the hydrogel and ionizable compound that may be made into tablets which will have a substantially zero-order release of the selected drug. In addition to the hydrogel and ionizable compound, the tabletted product may contain an inert solid diluent such as lactose, dextrose, maltose, fructose, corn starch, rice starch and the like. Other conventional additives such as binding agents such as polyvinylpyrrolidoine, starch, gelatin, microcrystalline cellulose and the like may be added to the tablet formulation. In addition, it is contemplated that coloring agents, stabilizers, lubricants such as stearic acid, palmitic acid, magnesium stearate, and the like may be added to the tabletting composition in amounts which are determined to produce the desired effect. Tablets may be made using conventional tabletting machines and appropriately sized dies.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The following examples are intended to illustrate the invention without limiting the scope of the invention:
EXAMPLE 1
A blend of diltiazem hydrochloride dispersed in hydroxypropylmethyl cellulose (HPMC) (100,000cps as measured in a 2wt% solution in water) was prepared by first separately passing the ingredients through a #40 US Standard mesh sieve and thereafter blending the mixture in a V-blender for 5 minutes. The blend was identified as Blend A and this blend had the following formulation:
Ingredient Diltiazem HC1 36.9wt%
HPMC (Methocel K100M) 27.0wt% Lactose,Anhydrous 35.1wt% Magnesium stearate 1.0wt% The powder was blended and compressed into capsule shaped tablets (0.70" x 0.29") with the compression set at twotons. An in vitro dissolution test was carried out separately using 900ml of an enzyme free simulated gastricfluid (pH 1.2); 900ml of an enzyme free simulatedintestinal fluid (pH 7.5) and a buffer solution (pH 6.2) substantially as described in USP XXII. The USPXXII method that was used was apparatus No. 2. The dissolution curve was prepared by determining at preset intervals the amount of dissolved diltiazem. The results are shown on Fig. 1 as curve A. Using the same procedures that were described above, tablets were prepared which contained 10% by weight of sodium chloride (B); 10% by weight of Na HPO (C) : 10% by weight of sodium lauryl sulfate (D) in place of 10% by weight of the anhydrous lactose that was employed in Blend A. The dissolution characteristics were determined according to the procedure set forth above and the characteristics are curves B, C and D of Fig. 1, respectively. The presence of the ionizable compound has the effect of flattening the release curve by preventing the initial burst of the active drug which results when a tablet, made from unmodified HPMC, is employed with diltiazem hydrochloride.
EXAMPLE 2
Using the procedure set forth in Example 1, tablets were made from the following Formulation:
Ingredient Diltiazem HC1 26.09wt.% HPMC (Methocel K100M) 30.00wt.%
Lactose, Anhydrous 33.39wt.% Sodium Chloride 6.52wt.%
Sodium Lauryl Sulfate 3.00wt.% Magnesium Stearate 1.00wt.%
The ingredients were blended and compressed into 0.28" round tablets using the procedure described in Example 1. The tablets were tested according to the procedure of Example 1 and the dissolution curve is set forth in Fig. 2. The results show that the tablets produced according to Example 2 have a substantially zero-order release rate.
EXAMPLE 3
Using the procedures of Example 1, tablets having the following composition are prepared:
Ingredient
Verapamil HC1 40.00wt.% HPMC 22.22wt.%
Sodium Chloride 10.00wt.%
Lactose, Anhydrous 26.78wt.% Magnesium stearate 1.00wt.%
The ingredients are blended and compressed using the procedure described in Example 1.

Claims

We claim:
1. A controlled release pharmaceutical composition which comprises:
(a) a drug;
(b) a hydrogel forming agent; and
(c) an effective amount of a non-toxic, pharmaceutically acceptable ionizable compound which is compatible with said drug and said hydrogel.
2. A pharmaceutical composition as defined in claim 1 wherein the hydrogel forming agent is hydroxy propyl methyl cellulose.
3. A pharmaceutical composition as defined in claim 2 wherein the non-toxic, pharmaceutically acceptable ionizable compound which is compatible with said drug and said hydrogel includes an alkali metal chloride.
4. A pharmaceutical composition as defined in claim 3 wherein the drug is diltiazem hydrochloride.
5. A pharmaceutical composition as defined in claim 3 wherein the drug is verapamil hydrochloride.
6. A pharmaceutical composition as defined in claim 3 which includes a sodium alkyl sulfate.
7. A pharmaceutical composition as defined in claim 6 wherein the sodium alkyl sulfate is sodium lauryl sulfate.
8. A tablet having the formulation of claim 1.
9. A tablet as defined in claim 8 wherein the drug is diltiazem hydrochloride.
10. A method of making a controlled release tablet having substantially zero-order release characteristics, said method consisting essentially of:
(a) combining a drug and a hydrogel to form a mixture, said hydrogel containing an effective amount of a non- toxic, pharmaceutically acceptable ionizable compound which is sufficient to impart zero-order release characteristics to said hydrogel; and
(b) thereafter tabletting said mixture to form tablets having substantially zero-order release characteristics.
11. A method as defined in claim 10 wherein the hydrogel is hydroxypropylmethyl cellulose.
12. A method as defined in claim 11 wherein the ionizable compound is a mixture of sodium chloride and sodium lauryl sulfate.
13. A method as defined in claim 12 wherein the drug is diltiazem hydrochloride.
EP95908570A 1994-02-14 1995-01-18 Controlled release hydrogel formulation Revoked EP0744942B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US195377 1994-02-14
US08/195,377 US5419917A (en) 1994-02-14 1994-02-14 Controlled release hydrogel formulation
PCT/US1995/000717 WO1995021607A1 (en) 1994-02-14 1995-01-18 Controlled release hydrogel formulation

Publications (3)

Publication Number Publication Date
EP0744942A1 true EP0744942A1 (en) 1996-12-04
EP0744942A4 EP0744942A4 (en) 1997-11-12
EP0744942B1 EP0744942B1 (en) 2002-07-24

Family

ID=22721188

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95908570A Revoked EP0744942B1 (en) 1994-02-14 1995-01-18 Controlled release hydrogel formulation

Country Status (10)

Country Link
US (1) US5419917A (en)
EP (1) EP0744942B1 (en)
JP (1) JPH10500658A (en)
AT (1) ATE220896T1 (en)
AU (1) AU680112B2 (en)
CA (1) CA2182587A1 (en)
DE (1) DE69527509T2 (en)
NZ (1) NZ279648A (en)
TW (1) TW340045B (en)
WO (1) WO1995021607A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
AU704222B2 (en) * 1995-03-24 1999-04-15 Genzyme Corporation Reduction of adhesions using controlled delivery of active oxygen inhibitors
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
IN186245B (en) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
JP4221068B2 (en) * 1997-12-17 2009-02-12 興和創薬株式会社 Theophylline sustained release tablet and method for producing the same
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
ATE267589T1 (en) 1998-04-03 2004-06-15 Egalet As COMPOSITION WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
DE69940557D1 (en) 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc A HYDROCOLLOID AND A DELIVERY-RELATED TABLET CONTAINING CELLULOSE ETHER
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
CA2778208C (en) * 2001-09-28 2015-11-10 Tntgamble Inc. Delivery system for biological component
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
EP1443910A1 (en) * 2001-11-02 2004-08-11 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
BR0117171A (en) * 2001-11-19 2004-10-26 Lupin Ltd Pharmaceutical composition for controlled release of a beta-lactam antibiotic
CA2472188C (en) * 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
SI1576138T1 (en) 2002-11-15 2017-07-31 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE602004025159D1 (en) * 2003-03-26 2010-03-04 Egalet As Matrix preparations for the controlled administration of drugs
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
HUE028598T2 (en) * 2007-06-08 2016-12-28 Boehringer Ingelheim Int Extended release formulation of nevirapine
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
KR20100020459A (en) * 2007-06-08 2010-02-22 아드레넥스 파마슈티컬스, 아이엔씨. Extended release formulation and method of treating adrenergic dysregulation
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
CN104185420B (en) 2011-11-30 2017-06-09 埃默里大学 Antiviral JAK inhibitor for treating or preventing retrovirus and other virus infection
BR112015000150A2 (en) 2012-07-06 2017-06-27 Egalet Ltd controlled release abuse deterrent pharmaceutical compositions
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
WO2015136377A2 (en) * 2014-03-11 2015-09-17 Redhill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA3029602A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of mirna and methods for treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) † 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) † 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
EP0233590A1 (en) † 1986-02-13 1987-08-26 Csk Corporation Method and apparatus for detecting focussing position
EP0309157A1 (en) * 1987-09-24 1989-03-29 American Home Products Corporation Sustained release etodolac
EP0484106A1 (en) * 1990-11-01 1992-05-06 Merck & Co. Inc. Controlled release formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220152A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4220153A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
FR2585246A1 (en) * 1985-07-26 1987-01-30 Cortial PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH04316515A (en) * 1991-04-12 1992-11-06 Shin Etsu Chem Co Ltd Sustained release tablet
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) † 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) † 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4389393B1 (en) † 1982-03-26 1985-10-22
EP0233590A1 (en) † 1986-02-13 1987-08-26 Csk Corporation Method and apparatus for detecting focussing position
EP0309157A1 (en) * 1987-09-24 1989-03-29 American Home Products Corporation Sustained release etodolac
EP0484106A1 (en) * 1990-11-01 1992-05-06 Merck & Co. Inc. Controlled release formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 9251 Derwent Publications Ltd., London, GB; Class A96, AN 92-420389 XP002039436 & JP 04 316 515 A (SHINETSU CHEM IND CO LTD) , 6 November 1992 *
See also references of WO9521607A1 †
Ventouras K. et al.: "Rôle de l'adification de matrices hydrophiles sur la libération de proncipes actifs peu solubles en milieu intestinal", PHARM. ACTA HELV., vol. 53, N°. 11 (1978), pp. 314-320 †

Also Published As

Publication number Publication date
US5419917A (en) 1995-05-30
DE69527509D1 (en) 2002-08-29
ATE220896T1 (en) 2002-08-15
AU680112B2 (en) 1997-07-17
EP0744942A4 (en) 1997-11-12
DE69527509T2 (en) 2003-02-27
CA2182587A1 (en) 1995-08-17
EP0744942B1 (en) 2002-07-24
JPH10500658A (en) 1998-01-20
NZ279648A (en) 1997-06-24
WO1995021607A1 (en) 1995-08-17
AU1683695A (en) 1995-08-29
TW340045B (en) 1998-09-11

Similar Documents

Publication Publication Date Title
AU680112B2 (en) Controlled release hydrogel formulation
US5399362A (en) Once-a-day metoprolol oral dosage form
FI113337B (en) Process for preparing a sustained-release oxybutynin formulation
JP2832248B2 (en) Controlled release preparation of metoprolol or metoprolol salt and method for producing the same
EP0384514B1 (en) Dual-action tablet
AU598280B2 (en) Sustained release pharmaceutical compositions in oral dosage form
US20060193912A1 (en) Controlled release O-desmethylvenlafaxine formulations
US20140242166A1 (en) Sustained release matrix systems for highly soluble drugs
WO2004019901A2 (en) Sustained release pharmaceutical composition
AU2005313262B2 (en) Tablets for the sustained release of indapamide and preparation method thereof
MXPA05002136A (en) Nitrofurantoin controlled release dosage form.
US20050271718A1 (en) Sustained release propafenone hydrochloride capsules
SK6942003A3 (en) Oral extended release formulation of gepirone
WO2000013675A1 (en) Methazolamide compositions and method of use
AU2003246326A1 (en) Sustained Release Matrix Systems for Highly Soluble Drugs
AU2006233161A1 (en) Sustained Release Matrix Systems for Highly Soluble Drugs
IL179194A (en) Pharmaceutical tablet and a process for preparing slow release formulation thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE DE DK FR GB IE IT NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970925

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE DE DK FR GB IE IT NL SE

17Q First examination report despatched

Effective date: 19990311

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE DE DK FR GB IE IT NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020724

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020724

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020724

REF Corresponds to:

Ref document number: 220896

Country of ref document: AT

Date of ref document: 20020815

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69527509

Country of ref document: DE

Date of ref document: 20020829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021024

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021024

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030120

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

26 Opposition filed

Opponent name: BAYER AG

Effective date: 20030423

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040115

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040127

Year of fee payment: 10

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20040330

Year of fee payment: 10

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050118

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050802

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050930

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 20060409